Adaptimmune Therapeutics Plc Institutional ownership

What is the Institutional ownership of Adaptimmune Therapeutics Plc?

The Institutional ownership of Adaptimmune Therapeutics Plc is 70.53%

What is the definition of Institutional ownership?



Institutional Ownership is the amount of a company’s available stock owned by mutual or pension funds, insurance companies, investment firms, endowments or other large entities that manage funds on the behalf of others.

Given the considerable sums of money that institutions invest, it is not surprising that they tend to be much more knowledgeable than the average investor when it comes to the companies and industries in which they have invested.

Institutional portfolio managers often meet personally with a company's top executives, and in many cases the research they conduct is further supported by equity analysts who evaluate prospective companies and industries in great depth before making specific investment recommendations.

Institutional ownership of companies in the Health Care sector on NASDAQ compared to Adaptimmune Therapeutics Plc

What does Adaptimmune Therapeutics Plc do?

adaptimmune llc is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary t-cell receptor platform that has the potential to transform the treatment of cancer. established in 2008, the company has grown from being privately held to one of the most successful biopharmaceutical initial public offerings (ipo) in 2015. with u.s. operations based in philadelphia, pa, adaptimmune is a company founded on strong science that has led to a robust pipeline of immuno-oncology product candidates, a growing research & development platform and ongoing plans for expansion. for more information about adaptimmune, please visit www.adaptimmune.com. if interested in joining our fast growing team, click on the careers tab of this page.

Companies with institutional ownership similar to Adaptimmune Therapeutics Plc